July 2004

Use of SCORTEN to Accurately Predict Mortality in Patients With Toxic Epidermal Necrolysis in the United States

Author Affiliations

Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004

Arch Dermatol. 2004;140(7):890-892. doi:10.1001/archderm.140.7.890

The SCORTEN is an illness severity score specific to toxic epidermal necrolysis (TEN) developed and validated in Europe by Bastuji-Garin et al.1 Recently, 2 reports of the use of the SCORTEN toassess the changes in mortality in patients treated with intravenous immune globulin have shown contradictory results, bringing into question the applicabilityof the SCORTEN outside Europe.2,3 We therefore retrospectively analyzed our patients with TEN before using intravenousimmune globulin to determine whether the SCORTEN would accurately predict mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview